Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 1, 2007, Pages 87-91

  Vergara, Salvador ^a   Macías, Juan ^a   Mira, José A ^a   García García, José A ^a   Merchante, Nicolás ^a   del Valle, José ^a   Abdel Kader, Laila ^a   Lozano, Fernando ^a   Gómez Mateos, Jesús M ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Antiretroviral agents; Hepatotoxicity; Highly active antiretroviral therapy; HIV HCV coinfection

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SIDE EFFECT; SUPERINFECTION; TREATMENT DURATION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; RETROSPECTIVE STUDIES;

EID: 33845908184     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl447     Document Type: Article

References (17)

1. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-8.
2. Mohsen AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus-infected patients. Gut 2003; 52: 1035-40.
3. Martínez-Sierra C, Arizcorreta A, Díaz F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36: 491-8.
4. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.
5. Bonacini M, Louie S, Bzowej N et al. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004; 18: 2039-45.
6. Merchante N, Girón-González JA, González-Serrano M et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 49-57.
7. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
8. Macias J, Castellano V, Merchante N et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS 2004; 18: 767-74.
9. Mehta SH, Thomas DL, Torbenson M et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41: 123-31.
10. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 1996.
11. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
12. Uberti-Foppa C, De Bona A, Galli L et al. Liver fibrosis in HIV-positive patients with hepatitis C virus: Role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006; 41: 63-7.
13. Macias J, Girón-González JA, González-Serrano M et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006; 55: 409-14.
14. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
15. Sulkowski M, Mehta S, Torbenson M et al. Unexpected significant liver disease among HIV/HCV-coinfected persons with minimal fibrosis on initial liver biopsy. In: Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 121, p. 108. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Bonnard P, Callard P, Guiard-Schmid JB et al. Assessment of fibrosis progression in patients dually infected by HIV and HCV. In: Abstracts of the Second International Workshop on HIV and Hepatitis Coinfection, Amsterdam, The Netherlands, 2006. Abstract 49. http://www.hivpresentation.com/index.cfm?vId=D8D3C03DE0C4-D510- 0E6AAFBBC5F458AC&cID=E2C31CB4-E0C4-D510- 0AC4D6D1E12A1D17&show=slide
17. Bruno R, Sacchi P, Patruno S et al. Hierarchy of liver-related major complications in a cohort of co-infected patients with compensated liver cirrhosis. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 873, p. 370. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.